Small molecule compound for treating rheumatoid arthritis and application thereof

A small molecular compound and rheumatoid technology, applied in the direction of organic active ingredients, medical preparations containing active ingredients, applications, etc., can solve the problems of lack of safe and effective therapeutic drugs, difficult treatment, failure of secondary treatment, etc.

Inactive Publication Date: 2018-12-28
LONGHUA HOSPITAL SHANGHAI UNIV OF TRADITIONAL CHINESE MEDICINE
View PDF0 Cites 4 Cited by
  • Summary
  • Abstract
  • Description
  • Claims
  • Application Information

AI Technical Summary

Problems solved by technology

The treatment of RA is very difficult, so far, there is still a lack of safe and effective therapeutic drugs
Modern medicine is mainly about anti-inflammation and reducing sequelae. Drugs such as TNFα inhibitors Etanercept, Infliximab and Adalimumab can reduce some objective symptom indicators such as swelling and tender joint counts to 50% in some RA patients. Its non-response, or the failure of the second treatment, an average of about 10% of patients discontinued each year

Method used

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
View more

Image

Smart Image Click on the blue labels to locate them in the text.
Viewing Examples
Smart Image
  • Small molecule compound for treating rheumatoid arthritis and application thereof
  • Small molecule compound for treating rheumatoid arthritis and application thereof
  • Small molecule compound for treating rheumatoid arthritis and application thereof

Examples

Experimental program
Comparison scheme
Effect test

experiment example

[0019] The CIA model of DBA / 1 mice was established. DBA / 1 female mice for 6-8 weeks, after adaptive feeding for 1 week, use bovine type II collagen and complete Freund's adjuvant (BCG concentration: 4 mg / ml), after complete emulsification, inject 100 μL intradermally into the back skin near the caudal vertebra (containing 100 μg of bovine type II collagen), after 42 days, the mouse lower limbs (below the ankle joint) or upper limbs (below the wrist joint) can appear obvious redness and swelling, and the incidence rate is about 90%. 42 days after the initial immunization of DBA / 1 mice, the modeled mice were randomly divided into groups, i.e. notopterythyl alcohol group and control group, with more than 10 mice in each group. In the notopterythyl alcohol group, notopterythyl alcohol was dissolved in 0.5% carboxymethylcellulose sodium (CMC-Na) to prepare a suspension, and in the control group, 0.5% CMC-Na was used. The dosage of notopterythyl alcohol is 40mg / kg. Oral administra...

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to view more

PUM

No PUM Login to view more

Abstract

The invention relates to a small molecule compound for treating rheumatoid arthritis. The concentration of notopterol serving as an active ingredient is 1-100 micro mole per liter. It is proved by ananimal experiment that notopterol can alleviate joint injury of mice suffering from collagen-induced rheumatoid arthritis, reduce inflammatory infiltrating area, bone defect and cartilage defect, alleviate inflammatory injury of ankle joints, inhibit the expression of LPS / IFN-gamma induced bone marrow macrophage inflammatory factor IL-1beta and alleviate symptoms of rheumatoid arthritis. The invention also discloses application of notopterol in preparation of medicine or health care products for treatment of rheumatoid arthritis.

Description

technical field [0001] The invention relates to a small molecule compound for treating rheumatoid arthritis, and proposes the application of the compound in preparing various forms of medicines or health food for preventing and treating rheumatoid arthritis. Background technique [0002] The prior art discloses that rheumatoid arthritis (Rheumatoid Arthritis, RA) is a chronic, systemic, progressive, autoimmune disease characterized by widespread persistent synovitis and symmetrical, destructive joint Lesions are characteristic. The treatment of RA is very difficult, so far, there is still a lack of safe and effective drugs. Modern medicine is mainly about anti-inflammation and alleviating sequelae. Drugs such as TNFα inhibitors Etanercept, Infliximab and Adalimumab can reduce some objective symptom indicators such as swelling and tender joint counts to 50% in some RA patients, but many patients still have problems in initial treatment. Its non-response, or the failure of t...

Claims

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to view more

Application Information

Patent Timeline
no application Login to view more
Patent Type & Authority Applications(China)
IPC IPC(8): A61K31/366A61P29/00A61P19/02
CPCA23V2002/00A61K31/366A23L33/105A23V2200/306A23V2250/21
Inventor 梁倩倩王拥军王琼徐浩施杞王腾腾齐晓凤贾庆运王怡茹刘洋王晓赟许崇卿刘利张利刘书芬李强赵永见
Owner LONGHUA HOSPITAL SHANGHAI UNIV OF TRADITIONAL CHINESE MEDICINE
Who we serve
  • R&D Engineer
  • R&D Manager
  • IP Professional
Why Eureka
  • Industry Leading Data Capabilities
  • Powerful AI technology
  • Patent DNA Extraction
Social media
Try Eureka
PatSnap group products

Browse by: Latest US Patents, China's latest patents, Technical Efficacy Thesaurus, Application Domain, Technology Topic.

© 2024 PatSnap. All rights reserved.Legal|Privacy policy|Modern Slavery Act Transparency Statement|Sitemap